SCHEMBL3386103

SCHEMBL3386103

O=C(N[C@H](CCO)c1ccccc1)C1SCCN1S(=O)(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGFR P43088 1/20 0.64
MMP9 P14780 5/20 0.43
MMP2 P08253 4/20 0.43
HSD11B1 P28845 2/20 0.42
MMP1 P03956 2/20 0.41
MMP3 P08254 2/20 0.41
ADAM17 P78536 1/20 0.41
PRKACA P17612 1/20 0.41
CDK8 P49336 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
PRKX P51817 1/20 0.41
PRKCQ Q04759 1/20 0.41
ROCK1 Q13464 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MMP8 P22894 1/20 0.40
MMP12 P39900 1/20 0.40
MMP14 P50281 1/20 0.40
CA12 O43570 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3382557 1.00 PTGFR (0.64) PTGFRMMP9MMP2HSD11B1MMP1
SCHEMBL3383620 1.00 PTGFR (0.64) PTGFRMMP9MMP2HSD11B1MMP1
SCHEMBL3382579 1.00 PTGFR (0.64) PTGFRMMP9MMP2HSD11B1MMP1
SCHEMBL3382653 1.00 PTGFR (0.64) PTGFRMMP9MMP2HSD11B1MMP1
SCHEMBL3381107 0.94 PTGFR (0.73) PTGFRMMP9MMP2HSD11B1MMP1
SCHEMBL3383804 0.94 PTGFR (0.62) PTGFRMMP9MMP2HSD11B1MMP3
SCHEMBL27049055 0.94 PTGFR (0.73) PTGFRMMP9MMP2HSD11B1MMP1
SCHEMBL3384077 0.94 PTGFR (0.64) PTGFRMMP9MMP2HSD11B1ALDH1A1
SCHEMBL3382048 0.94 PTGFR (0.73) PTGFRMMP9MMP2HSD11B1MMP1
SCHEMBL3919557 0.92 PTGFR (0.61) PTGFRMMP9MMP2HSD11B1MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487442-B1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR MERCK SERONO SA (CH) 2010-12-01 EP claimed
US-20050215605-A1 Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor MERCK SERONO SA (CH) 2005-09-29 US claimed
US-8415480-B2 Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor MERCK SERONO SA (CH) 2013-04-09 US disclosed
US-20050215605-A1 Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor MERCK SERONO SA (CH) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215605-A1 Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor TBXA2R, CNR2, PTGDR PTGFR 16/4885MMP9 4645/4885MMP2 2989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.